These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1988 related items for PubMed ID: 28318951

  • 1. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [Abstract] [Full Text] [Related]

  • 2. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [Abstract] [Full Text] [Related]

  • 3. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Masago K, Fujita S, Yoshida H, Zama K, Imai Y, Hirata Y.
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR.
    Cancer; 2019 Apr 01; 125(7):1038-1049. PubMed ID: 30548240
    [Abstract] [Full Text] [Related]

  • 5. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Honda H, Oda Y, Maehara Y.
    Cancer Med; 2017 Nov 01; 6(11):2552-2561. PubMed ID: 28980429
    [Abstract] [Full Text] [Related]

  • 6. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S, Kenmotsu H, Abe M, Watanabe R, Sugino T, Kobayashi H, Nakashima K, Wakuda K, Ono A, Taira T, Naito T, Murakami H, Ohde Y, Endo M, Akiyama Y, Nakajima T, Takahashi T.
    Int J Clin Oncol; 2018 Dec 01; 23(6):1052-1059. PubMed ID: 29948239
    [Abstract] [Full Text] [Related]

  • 7. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R, Murakami S, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Kusumoto M, Yamamoto N, Ohe Y.
    Med Oncol; 2019 Apr 27; 36(6):49. PubMed ID: 31030326
    [Abstract] [Full Text] [Related]

  • 8. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.
    J Clin Oncol; 2017 Dec 01; 35(34):3867-3876. PubMed ID: 29053400
    [Abstract] [Full Text] [Related]

  • 9. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
    Fujimoto D, Sato Y, Morimoto T, Uehara K, Ito M, Otsuka K, Nagata K, Sakanoue I, Hamakawa H, Nakagawa A, Takahashi Y, Imai Y, Tomii K.
    Clin Lung Cancer; 2018 Sep 01; 19(5):e667-e673. PubMed ID: 29844002
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
    Li W, Song P, Guo L, Liu X, Guo C, Ying J, Gao S.
    Thorac Cancer; 2019 Feb 01; 10(2):175-182. PubMed ID: 30536734
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    Edahiro R, Kanazu M, Kurebe H, Mori M, Fujimoto D, Taniguchi Y, Suzuki H, Hirano K, Yokoyama T, Morita M, Fukuda Y, Uchida J, Makio T, Tamiya M.
    PLoS One; 2019 Feb 01; 14(7):e0220570. PubMed ID: 31365588
    [Abstract] [Full Text] [Related]

  • 12. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y.
    Clin Lung Cancer; 2018 Mar 01; 19(2):120-129. PubMed ID: 29153898
    [Abstract] [Full Text] [Related]

  • 13. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P.
    Cancer Cytopathol; 2018 Apr 01; 126(4):264-274. PubMed ID: 29411536
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K, Horinouchi H, Tanaka M, Higashiyama R, Shinno Y, Sato J, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y.
    J Cancer Res Clin Oncol; 2021 Jan 01; 147(1):245-251. PubMed ID: 32705363
    [Abstract] [Full Text] [Related]

  • 15. Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
    Takamori S, Toyokawa G, Okamoto I, Takada K, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.
    Anticancer Res; 2018 Jan 01; 38(1):553-557. PubMed ID: 29277823
    [Abstract] [Full Text] [Related]

  • 16. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y.
    Surg Oncol; 2018 Mar 01; 27(1):88-94. PubMed ID: 29549910
    [Abstract] [Full Text] [Related]

  • 17. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
    Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC.
    Eur J Cancer; 2018 Sep 01; 101():201-209. PubMed ID: 30077125
    [Abstract] [Full Text] [Related]

  • 18. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L, Lin Z, Li N, Jiang J, Lu C, Du S, Zhang J, Wang Y, Chen J, Gong P.
    Zhongguo Fei Ai Za Zhi; 2021 Sep 20; 24(9):623-631. PubMed ID: 34455737
    [Abstract] [Full Text] [Related]

  • 19. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS.
    Lung Cancer; 2016 Jul 20; 97():73-80. PubMed ID: 27237031
    [Abstract] [Full Text] [Related]

  • 20. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR, Miller RA, Miller T, Deavers M, Gorman B, Mody D, Ge Y, Barrios R, Bernicker E, Kim M, Cagle PT.
    Arch Pathol Lab Med; 2017 Nov 20; 141(11):1529-1532. PubMed ID: 28829153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 100.